Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment

Novel strategies for prostate cancer therapy are required to overcome resistance to abiraterone and enzalutamide. Here, we show that increasing 3βHSD1 after abiraterone and enzalutamide treatment is essential for drug resistance, and biochanin A (BCA), as an inhibitor of 3βHSD1, overcomes drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Zejie, Yang, Tao, Liu, Ying, Gao, Yuanyuan, Hou, Zemin, Zhuang, Qian, He, Dongyin, Zhang, Xuebin, Tan, Qilong, Zhu, Xuyou, Qin, Yingyi, Chen, Xi, Xu, Chengdang, Bian, Cuidong, Wang, Xinan, Wang, Chenyang, Wu, Denglong, Huang, Shengsong, Li, Zhenfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133401/
https://www.ncbi.nlm.nih.gov/pubmed/35584629
http://dx.doi.org/10.1016/j.xcrm.2022.100608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133401/
https://www.ncbi.nlm.nih.gov/pubmed/35584629
http://dx.doi.org/10.1016/j.xcrm.2022.100608

Ejemplares similares